Department of Minimally Invasive Interventional Radiology, Key Laboratory of Molecular Target & Clinical Pharmacology, School of Pharmaceutical Sciences & the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, People's Republic of China.
Advanced Research Institute of Multidisciplinary Science, School of Life Science, School of Medical Technology (Institute of Engineering Medicine), Key Laboratory of Molecular Medicine and Biotherapy, Key Laboratory of Medical Molecular Science and Pharmaceutics Engineering, Beijing Institute of Technology, Beijing, 100081, China.
J Nanobiotechnology. 2022 May 19;20(1):236. doi: 10.1186/s12951-022-01451-4.
Nanomedicines (NMs) have emerged as an efficient approach for developing novel treatment strategies against a variety of diseases. Over the past few decades, NM formulations have received great attention, and a large number of studies have been performed in this field. Despite this, only about 60 nano-formulations have received industrial acceptance and are currently available for clinical use. Their in vivo pharmaceutical behavior is considered one of the main challenges and hurdles for the effective clinical translation of NMs, because it is difficult to monitor the pharmaceutic fate of NMs in the biological environment using conventional pharmaceutical evaluations. In this context, non-invasive imaging modalities offer attractive solutions, providing the direct monitoring and quantification of the pharmacokinetic and pharmacodynamic behavior of labeled NMs in a real-time manner. Imaging evaluations have great potential for revealing the relationship between the physicochemical properties of NMs and their pharmaceutical profiles in living subjects. In this review, we introduced imaging techniques that can be used for in vivo NM evaluations. We also provided an overview of various studies on the influence of key parameters on the in vivo pharmaceutical behavior of NMs that had been visualized in a non-invasive and real-time manner.
纳米药物（NMs）已成为针对多种疾病开发新型治疗策略的有效方法。在过去的几十年中，NM 制剂受到了极大的关注，并且在该领域进行了大量的研究。尽管如此，只有约 60 种纳米制剂获得了工业认可，并且目前可用于临床使用。它们的体内药物行为被认为是 NM 有效临床转化的主要挑战和障碍之一，因为很难使用常规药物评估来监测 NM 在生物环境中的药物命运。在这种情况下，非侵入性成像方式提供了有吸引力的解决方案，可实时直接监测和定量标记 NM 的药代动力学和药效动力学行为。成像评估具有揭示 NM 的物理化学性质与其在活体研究对象中的药物特征之间关系的巨大潜力。在这篇综述中，我们介绍了可用于体内 NM 评估的成像技术。我们还概述了各种研究，这些研究以非侵入性和实时的方式可视化了关键参数对 NM 体内药物行为的影响。
Zotero 插件
